Brian Wynne

4.4k total citations · 2 hit papers
70 papers, 2.6k citations indexed

About

Brian Wynne is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Brian Wynne has authored 70 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Infectious Diseases, 38 papers in Virology and 18 papers in Epidemiology. Recurrent topics in Brian Wynne's work include HIV/AIDS drug development and treatment (59 papers), HIV Research and Treatment (38 papers) and HIV/AIDS Research and Interventions (22 papers). Brian Wynne is often cited by papers focused on HIV/AIDS drug development and treatment (59 papers), HIV Research and Treatment (38 papers) and HIV/AIDS Research and Interventions (22 papers). Brian Wynne collaborates with scholars based in United States, United Kingdom and Spain. Brian Wynne's co-authors include Keith A. Pappa, Catherine Granier, Sharon Walmsley, Sherene Min, Michael Aboud, Garrett Nichols, Laurent Hocqueloux, Julie Borland, Félix Gutiérrez and Antonio Antela and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

Brian Wynne

64 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

2013 593 citations Sharon Walmsley, Antonio Antela et al. New England Journal of Medicine profile →
Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

2018 243 citations Josep M. Llibre, Chien‐Ching Hung et al. The Lancet profile →

Peers

Countries citing papers authored by Brian Wynne

Since Specialization

Citations

This map shows the geographic impact of Brian Wynne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian Wynne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian Wynne more than expected).

Fields of papers citing papers by Brian Wynne

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian Wynne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian Wynne. The network helps show where Brian Wynne may publish in the future.

Co-authorship network of co-authors of Brian Wynne

This figure shows the co-authorship network connecting the top 25 collaborators of Brian Wynne. A scholar is included among the top collaborators of Brian Wynne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian Wynne. Brian Wynne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide–Based Regimen in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1: Subgroup Analysis of Participants With Elvitegravir as Baseline Third Agent From the TANGO Study 2024 ·Open Forum Infectious Diseases ·Mounir Ait‐Khaled, J Oyee, (unknown), Brian Wynne, (unknown), (unknown), Tao Wang	0
2	Dolutegravir + Lamivudine vs. Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Very-Low-Level HIV-1 Replication through 144 Weeks in the GEMINI-1 and GEMINI-2 Studies 2024 ·Viruses ·Mark Underwood, (unknown), Ruolan Wang, (unknown), J Oyee, Brian Wynne, (unknown), (unknown), Choy Man, Jörg Sievers	2
3	Patient-Reported Outcomes After Switching to a 2-Drug Regimen of Fixed-Dose Combination Dolutegravir/Lamivudine: 48-Week Results from the SALSA Study 2024 ·AIDS and Behavior ·Princy Kumar, Amanda Clarke, (unknown), Miguel García Deltoro, Simona Di Giambenedetto, Carlos Brites, Laurent Hocqueloux, Po‐Liang Lu, J Oyee, Alan Oglesby, Brian Wynne, (unknown), (unknown), (unknown), (unknown), Julie Priest	0
4	Cardiometabolic Parameters 3 Years After Switch to Dolutegravir/Lamivudine vs Maintenance of Tenofovir Alafenamide–Based Regimens 2023 ·Open Forum Infectious Diseases ·Rachel L. Batterham, Núria Espinosa, Christine Katlama, Mehri S. McKellar, Stefan Scholten, Don Smith, Mounir Ait‐Khaled, Nisha George, Jonathan Wright, (unknown), (unknown), Brian Wynne, Jean van Wyk	6
5	Pharmacokinetic and pharmacokinetic/pharmacodynamic characterization of the dolutegravir/rilpivirine two‐drug regimen in SWORD‐1/‐2 phase 3 studies 2023 ·British Journal of Clinical Pharmacology ·Rashmi Mehta, (unknown), Konstantinos Angelis, (unknown), Lesley Kahl, (unknown), Jessica Matthews, Brian Wynne, Herta Crauwels, Mark Underwood, Kimberly K. Adkison	2
6	Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks 2023 ·Open Forum Infectious Diseases ·Charlotte-Paige Rolle, Mezgebe Berhe, Tulika Singh, Roberto Ortiz, (unknown), Moti Ramgopal, Dushyantha Jayaweera, Peter A. Leone, Jessica Matthews, (unknown), Mark Underwood, Konstantinos Angelis, Brian Wynne, (unknown), Christopher Nguyen, Jean van Wyk, Andrew Zolopa	11
7	Switching to dolutegravir/lamivudine (DTG/3TC) fixed-dose combination (FDC) is non-inferior to continuing a tenofovir alafenamide (TAF)-based regimen (TBR) in maintaining virological suppression through 96 weeks (TANGO study) 2021 ·HIV Medicine ·Jean van Wyk, F. Ajana, Fiona Bisshop, Christoph Stephan, Olayemi Osiyemi, Joaquín Portilla, Jean‐Pierre Routy, Christoph Wyen, Mounir Ait‐Khaled, (unknown), Keith A. Pappa, (unknown), (unknown), Brian Wynne, Michael Aboud, Kimberly Y. Smith	0
8	Dolutegravir-based regimens in treatment-naive and treatment-experienced aging populations: analyses of 6 phase III clinical trials 2021 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), M. van der Kolk, (unknown), Richard Grove, Brian Wynne, Jean van Wyk, Andrew Clark	7
9	Impact of treatment adherence on efficacy of dolutegravir plus lamivudine and dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled analysis of the GEMINI-1 and GEMINI-2 clinical studies 2021 ·SHILAP Revista de lepidopterología ·Mounir Ait‐Khaled, Juan Sierra Madero, Vicente Estrada, Roberto Gulminetti, Debbie Hagins, Hung‐Chin Tsai, Choy Man, Jörg Sievers, Richard Grove, Andrew Zolopa, Brian Wynne, Jean van Wyk	6
10	The Effect of Moderate- and High-Fat Meals on the Bioavailability of Dolutegravir/Rilpivirine Fixed-Dose Combination Tablet 2020 ·SHILAP Revista de lepidopterología ·Rashmi Mehta, Joseph Piscitelli, Adrian J. Wolstenholme, (unknown), Herta Crauwels, Brian Wynne, Kimberly K. Adkison	1
11	Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies breakdown → 2018 ·The Lancet ·Josep M. Llibre, Chien‐Ching Hung, Cynthia Brinson, Francesco Castelli, Pierre‐Marie Girard, Lesley Kahl, Elizabeth A. Blair, (unknown), Brian Wynne, Kati Vandermeulen, Mark Underwood, (unknown), Martin Gartland, Michael Aboud	243
12	Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health 2017 ·AIDS ·Grace A. McComsey, Sergio Lupo, (unknown), (unknown), (unknown), Lesley Kahl, (unknown), Brian Wynne, Kati Vandermeulen, Martin Gartland, (unknown), Michael Aboud	43
13	Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation 2016 ·European Journal of Clinical Pharmacology ·Ivy Song, Steve Weller, (unknown), Julie Borland, Brian Wynne, (unknown), (unknown), Stephen C. Piscitelli	23
14	No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjects 2016 ·BMC Infectious Diseases ·Lisa Ross, Ivy Song, Niki Arya, (unknown), Jian Zong, Shu‐Pang Huang, Timothy Eley, Brian Wynne, Ann M. Buchanan	5
15	Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment 2013 ·European Journal of Clinical Pharmacology ·S Weller, Julie Borland, Shuguang Chen, Mark Johnson, Paul Savina, Brian Wynne, Toshihiro Wajima, Amanda Peppercorn, Stephen C. Piscitelli	48
16	Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection breakdown → 2013 ·New England Journal of Medicine ·Sharon Walmsley, Antonio Antela, Nathan Clumeck, Dan Duiculescu, (unknown), Félix Gutiérrez, Laurent Hocqueloux, Franco Maggiolo, Uriel Sandkovsky, Catherine Granier, Keith A. Pappa, Brian Wynne, Sherene Min, Garrett Nichols	593
17	Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains 2005 ·International Journal of Antimicrobial Agents ·Thomas M. File, Javier Garau, Michael R. Jacobs, Brian Wynne, Monique Twynholm, Elchonon M. Berkowitz	15
18	Large Dosage Amoxicillin/Clavulanate, Compared With Azithromycin, for the Treatment of Bacterial Acute Otitis Media in Children 2005 ·The Pediatric Infectious Disease Journal ·Alejandro Hoberman, Ron Dagan, Eugene Leibovitz, Andrés Rosenblüt, Candice E. Johnson, (unknown), Rajesh Bandekar, Brian Wynne	50
19	Multinational study of pneumococcal serotypes causing acute otitis media in children 2002 ·The Pediatric Infectious Disease Journal ·William P. Hausdorff, Greg Yothers, Ron Dagan, Terhi Kilpi, Stephen I. Pelton, Robert Cohen, Michael R. Jacobs, Sheldon L. Kaplan, Corinne Lévy, Eduardo López, Edward O. Mason, Vassiliki Syriopoulou, Brian Wynne, John Bryant	98
20	Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/clavulanate 2002 ·International Journal of Antimicrobial Agents ·Thomas M. File, Michael R. Jacobs, Michael D. Poole, Brian Wynne	35

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact